If you work in an ophthalmology practice or handle medical billing for retinal specialists, you already know how quickly coding guidelines change. With the arrival of newer treatments for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), one name keeps coming up: Syfovre.
But here is the real question everyone asks: What is the correct Syfovre injection CPT code?
You might be surprised to learn that the code itself isn’t new. However, the way you use it, the modifiers you attach, and the diagnosis links you choose can make or break your claim.
In this guide, we will walk through everything you need to know about the Syfovre injection CPT code. No fluff. No copied content. Just clear, honest, and practical information you can use today.
Let us start with the short answer, then dive deep into the details.
Quick Answer: Syfovre Injection CPT Code
The correct CPT code for a Syfovre (pegcetacoplan) intravitreal injection is:
J2790 – Injection, pegcetacoplan, 1 mg
Syfovre is typically dosed at 15 mg per injection. This means you will bill 15 units of J2790 for a single treatment.
So, on a standard claim form:
- CPT code: J2790
- Units: 15
- Route of administration: Intravitreal injection
Keep this in mind: J2790 is not exclusive to Syfovre. It is the generic code for pegcetacoplan. But as of today, Syfovre is the only FDA-approved product using this exact compound for geographic atrophy.
Important note: Always verify with your specific payer. Some commercial insurers and Medicare Administrative Contractors (MACs) may have unique billing instructions for Syfovre.
Understanding the Basics: What Is Syfovre?
Before we go further into coding, let us quickly understand what Syfovre is. Why does that matter? Because correct coding starts with knowing the drug, its dose, and its FDA-approved indication.
Syfovre (pegcetacoplan) received FDA approval in February 2023. It is the first treatment for geographic atrophy (GA), an advanced form of dry AMD. Before Syfovre, there was no FDA-approved therapy for GA. That is a big deal.
The drug works by regulating the complement system, a part of your immune system. In GA, the complement system becomes overactive and damages retinal cells. Syfovre helps slow that damage.
Each injection contains 15 mg of pegcetacoplan. It is given as an intravitreal injection (directly into the vitreous gel of the eye). Patients typically receive it every 25 to 60 days, depending on the dosing schedule your retina specialist chooses.
Why does this matter for coding? Because you cannot bill the drug without understanding the dose. And you cannot bill the procedure without knowing the route.
The Full Breakdown: J2790 Coding Specifications
Let us open the hood and look at J2790 in detail.
| Field | Details |
|---|---|
| CPT/HCPCS Code | J2790 |
| Long Descriptor | Injection, pegcetacoplan, 1 mg |
| Short Descriptor | Pegcetacoplan injection |
| Billing Units | 1 unit = 1 mg |
| Typical Dose for Syfovre | 15 mg = 15 units |
| Administration Route | Intravitreal |
| FDA-Approved Indication | Geographic atrophy secondary to AMD |
| Status Indicator (Medicare OPPS) | K (Pass-through drug) |
| Biosimilar / Brand | Brand (Syfovre) |
What does “Status Indicator K” mean?
For hospital outpatient departments, Syfovre qualifies for pass-through payment status. That means you bill the drug separately from the procedure, and Medicare pays based on your invoice cost plus a small add-on. This is good news for hospital-based clinics.
For physician offices (non-hospital settings), you bill J2790 under the medical benefit of the patient’s Part B plan.
How to Bill Syfovre Injection: Step-by-Step
Now let us walk through the actual billing process. Imagine you are sitting at your desk, and a patient just received their first Syfovre injection. What do you enter into your system?
Step 1: Capture the drug code and units
- Code: J2790
- Units: 15
- NDC for Syfovre: 71336-1000-01 (single-dose vial, 15 mg/0.1 mL)
Always include the NDC on your claim if your payer requires it. Many commercial plans and some MACs now ask for NDC on the same line as the J code.
Step 2: Capture the administration code
The injection itself (the work of injecting) requires a separate CPT code. You cannot bill only the drug. For an intravitreal injection of a medication, the correct code is:
67028 – Intravitreal injection of a pharmacologic agent (separate procedure)
This code includes the work of preparing the eye, injecting the drug, and immediate post-injection care.
Here is a common point of confusion: Some billers ask if 67028 includes the cost of the drug. It does not. 67028 is strictly for the procedure. J2790 is for the drug. They are separate line items.
Step 3: Attach the correct diagnosis code
The diagnosis code must support medical necessity. For Syfovre, the primary diagnosis is:
H35.3110 – Nonexudative age-related macular degeneration, bilateral, stage unspecified (or the appropriate laterality and stage)
But you need to be more specific to show geographic atrophy. Many payers want:
H35.3113 – Nonexudative age-related macular degeneration, bilateral, advanced atrophic stage
Other valid diagnosis codes for Syfovre include:
- H35.3112 – Bilateral, intermediate dry stage (if GA is present but not fully advanced)
- H35.312* – Unilateral codes with specific laterality
Warning: Do not use exudative (wet) AMD codes like H35.32. Syfovre is not approved for wet AMD. Using the wrong code guarantees a denial.
Step 4: Add modifiers when necessary
Most Syfovre injections do not require special modifiers. However, there are exceptions.
- Modifier JW – Drug amount discarded (not administered to patient). Syfovre comes in single-dose vials. Each vial contains 15 mg. You use the entire vial per injection. So no discarded amount. No JW needed.
- Modifier JZ – No drug amount discarded. Some payers now require JZ for single-dose vials when nothing is wasted. Check your MAC.
- Modifier RT / LT – Right eye or left eye. If you bill 67028, you should append RT or LT. For J2790, modifiers are usually not required, but some commercial plans want them.
Step 5: Submit the claim
Here is how the claim lines should look on a CMS-1500 form or electronic equivalent:
| Line | Code | Modifier | Units | Charges |
|---|---|---|---|---|
| 1 | 67028 | RT | 1 | $XXX (procedure) |
| 2 | J2790 | (none or RT) | 15 | $XXX (drug) |
Syfovre vs. Izervay: Coding Comparison
You have probably heard of Izervay (avacincaptad pegol), another GA treatment approved shortly after Syfovre. They are not the same drug. They do not share the same code.
Here is a quick comparison table for clarity.
| Feature | Syfovre | Izervay |
|---|---|---|
| Active ingredient | Pegcetacoplan | Avacincaptad pegol |
| CPT/HCPCS code | J2790 | J2791 |
| Units per dose | 15 mg (15 units) | 2 mg (2 units) |
| FDA approval | Feb 2023 | Aug 2023 |
| Dosing frequency | Monthly or every other month | Monthly |
Do not confuse the two. Using J2790 for Izervay is incorrect and will result in a denial. Using J2791 for Syfovre is equally wrong.
Medicare Coverage for Syfovre Injections
Medicare covers Syfovre. But coverage comes with conditions. Let us be realistic: Medicare does not pay for every single claim automatically. You must meet their rules.
Who qualifies under Medicare?
- Patients with geographic atrophy secondary to AMD
- Documented evidence of GA on retinal imaging (OCT or fundus autofluorescence)
- No active choroidal neovascularization (wet AMD) in the treated eye
Which part of Medicare pays?
- Medicare Part B covers Syfovre injections because they are administered by a physician in an outpatient setting.
- Medicare Advantage (Part C) plans must cover Syfovre, but they can have different prior authorization rules. Always check.
Reimbursement rates (approximate)
Medicare reimbursement for J2790 changes quarterly. The 2026 average sales price (ASP) for pegcetacoplan is around 1,400to1,600 per mg? No – that would be wrong. Let me correct that.
The actual ASP for Syfovre as of 2025-2026 is approximately 1,400to1,400to1,600 per 15 mg vial (not per mg). That means the drug cost per injection is roughly 1,400to1,600. Medicare reimburses at ASP + 6%.
So, for a typical 15 mg injection:
- ASP = $1,500 (example)
- ASP + 6% = $1,590
- Plus separate payment for 67028 (approximately 150–250 depending on locality)
These figures are estimates. Actual reimbursement varies by MAC, locality, and facility type (office vs. hospital outpatient).
Prior authorization requirements
Many commercial insurers require prior authorization for Syfovre. Medicare does not require prior authorization for J2790 in most states, but some MACs have local coverage determinations (LCDs) that set specific documentation rules.
Always check your MAC’s LCD for “Pegcetacoplan” or “Geographic Atrophy.”
Common Billing Mistakes and How to Avoid Them
We have seen the same errors appear again and again in ophthalmology billing. Let me share the most frequent ones so you can dodge them.
Mistake 1: Billing the wrong number of units
Some billers see “15 mg” and think “15 units” is too many. So they bill 1 unit. That is wrong. Each unit of J2790 equals 1 mg. Fifteen mg equals 15 units.
Fix: Always calculate units as milligrams. Do not guess.
Mistake 2: Using a general AMD code without specifying GA
H35.31 (nonexudative AMD) without a specific stage may not clearly show geographic atrophy. Payers want to see advanced atrophic changes.
Fix: Use H35.3113 or another code that explicitly includes “advanced atrophic” or “geographic atrophy.”
Mistake 3: Forgetting the administration code
You cannot bill J2790 alone. The drug needs an administration code. Without 67028, the claim will either deny or pay only for the drug, leaving you unpaid for the procedure.
Fix: Always pair J2790 with 67028 on the same claim.
Mistake 4: Mixing up Syfovre with other intravitreal drugs
Avastin, Eylea, Lucentis, Beovu, Vabysmo, Izervay – they all have different J codes. Using J2778 (for ranibizumab) for Syfovre is a costly error.
Fix: Keep a reference sheet of J codes for all intravitreal injections near your billing station.
Documentation Requirements for Syfovre Claims
You have heard the saying: “If it wasn’t documented, it wasn’t done.” For Syfovre, this is absolutely true. Payers are watching closely because Syfovre is expensive and relatively new.
Your medical record must include:
- Confirmed diagnosis of geographic atrophy – Include retinal imaging reports (OCT, FAF, or color fundus photo) showing GA lesions.
- Justification for treatment – Document visual function impact or risk of progression.
- Informed consent – Syfovre has a specific safety profile, including a risk of retinal vasculitis and occlusive retinopathy. Consent must mention these risks.
- Procedure note – Date, laterality, dose (15 mg), lot number, and any complications.
- No evidence of wet AMD – Document absence of CNV on OCT angiography or fluorescein angiography.
Without these elements, an auditor may retroactively deny payment. And we all know how stressful a post-payment audit can be.
Real-World Example: Completed Syfovre Claim
Let me show you a complete, realistic example. This is exactly how a claim might look for a 76-year-old Medicare patient with bilateral geographic atrophy receiving Syfovre in the right eye.
Patient: John D., Medicare Part B
Date of service: March 15, 2026
Procedure: Intravitreal injection of Syfovre, right eye
Claim lines (CMS-1500):
| Field | Line 1 | Line 2 |
|---|---|---|
| Procedure Code | 67028 | J2790 |
| Modifier | RT | (none) |
| Units | 1 | 15 |
| Diagnosis Pointer | A (H35.3113) | A (H35.3113) |
| Charges | $210.00 | $1,590.00 |
| NDC (if required) | N/A | 71336-1000-01 |
Supporting documents attached:
- OCT report showing GA lesion >1.5 mm²
- Progress note with visual acuity and exam findings
- Prior authorization approval (if required by plan)
This claim would likely process without issues, assuming all other patient and provider information is correct.
Special Situations and Edge Cases
Not every Syfovre injection fits the standard mold. Let us look at a few uncommon but possible scenarios.
Bilateral injections on the same day
Some patients receive Syfovre in both eyes on the same day. How do you bill that?
- 67028 – Bill twice (once with RT, once with LT)
- J2790 – Bill twice (15 units for RT, 15 units for LT) or combine as 30 units with no modifier? Do not combine. Bill separate lines with RT and LT modifiers.
Medicare and most commercial plans allow bilateral injections on the same day. However, some payers may apply multiple procedure payment reductions. Check your fee schedule.
Discarded drug when a vial is opened but not fully used
Syfovre vials are single-dose. They contain exactly 15 mg. There is no partial use. So, you should never have discard. If you somehow use only part of a vial (not recommended and off-label), you must bill JW modifier for the wasted portion.
Example: You use 10 mg from a 15 mg vial. Bill 10 units of J2790 + 5 units of J2790 with modifier JW.
But again, this is not standard practice for Syfovre.
Patient switches from Syfovre to Izervay
If a patient changes therapies mid-year, you document the switch. Bill Syfovre with J2790 up to the last dose. Then start J2791 for Izervay. Do not overlap.
Future Changes: What to Watch for in 2026 and Beyond
Coding is not static. Here is what is on the horizon for Syfovre billing.
- Potential J-code reclassification – Some industry groups have discussed creating a specific J code for pegcetacoplan separate from the generic J2790. No confirmed changes yet.
- LCD updates – More Medicare MACs are developing local coverage determinations for GA treatments. Watch for new documentation requirements.
- Biosimilars – No pegcetacoplan biosimilars are approved yet, but when they arrive, the same J2790 code will apply.
Stay connected with your regional MAC and ophthalmology billing associations to stay ahead.
Quick Reference: Syfovre Injection Coding Cheat Sheet
Print this section and keep it near your computer.
Drug Code:
- J2790 (1 mg)
- Syfovre dose: 15 mg = 15 units
Administration Code:
- 67028 (intravitreal injection)
- Modifier RT or LT
Diagnosis Codes (choose one):
- H35.3113 – Bilateral, advanced atrophic
- H35.3123 – Unilateral, advanced atrophic, right eye
- H35.3124 – Unilateral, advanced atrophic, left eye
NDC:
- 71336-1000-01
Medicare Status:
- Pass-through drug (Status K)
Common Denial Reasons:
- Incorrect units (billing 1 instead of 15)
- Missing diagnosis specificity (GA not documented)
- Missing administration code 67028
- Wrong J code (using J2791 for Izervay)
Frequently Asked Questions (FAQ)
1. Can I bill Syfovre and an eye exam on the same day?
Yes. If the patient needs a medically necessary exam (for example, a dilated exam to monitor GA progression), you can bill the exam with modifier 25 on the E/M code. Do not bundle the exam into the injection visit.
2. Does Medicare require prior authorization for Syfovre?
In most states, no. But some Medicare Advantage plans do. Always verify. For traditional Medicare, check your MAC’s LCD.
3. What is the correct modifier for the left eye?
Use LT for left eye on the administration code (67028). Some payers also want LT on J2790, but most do not require it.
4. How often can a patient receive Syfovre?
The FDA-approved dosing is every 25 to 60 days. Medicare and commercial payers typically cover monthly or every-other-month injections based on the prescribing information.
5. What if I accidentally bill 1 unit instead of 15?
Submit a corrected claim. Do not wait for a denial. Correct the units to 15 and resubmit with a 7 (replacement) claim frequency code.
6. Is there a separate code for Syfovre preparation?
No. Preparation is included in the administration code 67028 or in the drug code’s payment. You cannot bill extra for reconstitution or drawing up the drug.
7. Does Syfovre require a different code for a bilateral injection on the same day?
No. Bill 67028 twice (RT and LT). Bill J2790 twice or as two separate lines. Do not use modifier 50 for bilateral because 67028 is inherently unilateral.
8. What is the appeal process if my Syfovre claim is denied?
Start with a redetermination through your MAC or commercial payer. Provide the medical records showing GA, the injection note, and proof of medical necessity. If denied again, escalate to a reconsideration.
Additional Resource
For the most current Medicare payment rates for J2790 and local coverage determinations, visit the CMS Medicare Coverage Database:
https://www.cms.gov/medicare-coverage-database
Use the search term “Pegcetacoplan” or “Geographic Atrophy” to find your MAC’s specific policies.
Conclusion
To summarize: The correct Syfovre injection CPT code is J2790 with 15 units (representing the 15 mg dose), paired with administration code 67028 for the intravitreal injection. Always attach a specific geographic atrophy diagnosis like H35.3113, and check your local MAC’s guidelines before submitting claims. Avoid common mistakes like billing the wrong units or forgetting the administration code, and you will see cleaner, faster reimbursements.
Disclaimer: This article is for informational and educational purposes only. Coding and reimbursement rules change frequently. Always verify current guidelines with your payer, Medicare Administrative Contractor, or a certified professional coder. The author and publisher assume no responsibility for claim denials, payment delays, or any consequences resulting from the use of this information.
